PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis

Vasiliki Koika, Zongmin Zhou, Ioannis Vasileiadis, Charis Roussos, Federica Finetti, Martina Monti, Lucia Morbidelli, Andreas Papapetropoulos

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) stimulates nitric oxide (NO) production, which mediates many of its angiogenic actions. However, the angiogenic pathways that operate downstream of NO following VEGF treatment are not well characterized. Herein, we used DT-2 and DT-3, two highly selective cGMP-dependent protein kinase I peptide inhibitors to determine the contribution of PKG-I in VEGF-stimulated angiogenesis. Incubation of chicken chorioallantoic membranes (CAM) with PKG-I peptide inhibitors decreased vascular length in a dose-dependent manner, with DT-3 being more effective than DT-2. Moreover, inhibition of PKG-I with DT-3 abolished the angiogenic response elicited by VEGF in the rabbit eye cornea. PKG-I inhibition also blocked VEGF-stimulated vascular leakage. In vitro, treatment of cells with VEGF stimulated phosphorylation of the PKG substrate VASP through VEGFR2 activation; the VEGF-stimulated VASP phosphorylation was reduced by DT-2. Pre-treatment of cells with DT-2 or DT-3 inhibited VEGF-stimulated mitogen-activated protein kinase cascades (ERK1/2 and p38), growth, migration and sprouting of endothelial cells. The above observations taken together identify PKG-I as a downstream effector of VEGFR2 in EC and provide a rational basis for the use of PKG-I inhibitors in disease states characterized by excessive neovascularization.

Original languageEnglish (US)
Pages (from-to)215-222
Number of pages8
JournalVascular Pharmacology
Volume53
Issue number5-6
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Blood Vessels
Cyclic GMP-Dependent Protein Kinase Type I
Nitric Oxide
Phosphorylation
Chorioallantoic Membrane
Peptides
Mitogen-Activated Protein Kinases
Cornea
Chickens
Endothelial Cells
Rabbits
Growth

Keywords

  • Angiogenesis
  • CGMP
  • PKG
  • Vascular endothelium
  • VEGF

ASJC Scopus subject areas

  • Physiology
  • Molecular Medicine
  • Pharmacology

Cite this

PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis. / Koika, Vasiliki; Zhou, Zongmin; Vasileiadis, Ioannis; Roussos, Charis; Finetti, Federica; Monti, Martina; Morbidelli, Lucia; Papapetropoulos, Andreas.

In: Vascular Pharmacology, Vol. 53, No. 5-6, 01.11.2010, p. 215-222.

Research output: Contribution to journalArticle

Koika, V, Zhou, Z, Vasileiadis, I, Roussos, C, Finetti, F, Monti, M, Morbidelli, L & Papapetropoulos, A 2010, 'PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis', Vascular Pharmacology, vol. 53, no. 5-6, pp. 215-222. https://doi.org/10.1016/j.vph.2010.08.004
Koika V, Zhou Z, Vasileiadis I, Roussos C, Finetti F, Monti M et al. PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis. Vascular Pharmacology. 2010 Nov 1;53(5-6):215-222. https://doi.org/10.1016/j.vph.2010.08.004
Koika, Vasiliki ; Zhou, Zongmin ; Vasileiadis, Ioannis ; Roussos, Charis ; Finetti, Federica ; Monti, Martina ; Morbidelli, Lucia ; Papapetropoulos, Andreas. / PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis. In: Vascular Pharmacology. 2010 ; Vol. 53, No. 5-6. pp. 215-222.
@article{50609c42d3464d41b1f29e6fbb094e2b,
title = "PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis",
abstract = "Vascular endothelial growth factor (VEGF) stimulates nitric oxide (NO) production, which mediates many of its angiogenic actions. However, the angiogenic pathways that operate downstream of NO following VEGF treatment are not well characterized. Herein, we used DT-2 and DT-3, two highly selective cGMP-dependent protein kinase I peptide inhibitors to determine the contribution of PKG-I in VEGF-stimulated angiogenesis. Incubation of chicken chorioallantoic membranes (CAM) with PKG-I peptide inhibitors decreased vascular length in a dose-dependent manner, with DT-3 being more effective than DT-2. Moreover, inhibition of PKG-I with DT-3 abolished the angiogenic response elicited by VEGF in the rabbit eye cornea. PKG-I inhibition also blocked VEGF-stimulated vascular leakage. In vitro, treatment of cells with VEGF stimulated phosphorylation of the PKG substrate VASP through VEGFR2 activation; the VEGF-stimulated VASP phosphorylation was reduced by DT-2. Pre-treatment of cells with DT-2 or DT-3 inhibited VEGF-stimulated mitogen-activated protein kinase cascades (ERK1/2 and p38), growth, migration and sprouting of endothelial cells. The above observations taken together identify PKG-I as a downstream effector of VEGFR2 in EC and provide a rational basis for the use of PKG-I inhibitors in disease states characterized by excessive neovascularization.",
keywords = "Angiogenesis, CGMP, PKG, Vascular endothelium, VEGF",
author = "Vasiliki Koika and Zongmin Zhou and Ioannis Vasileiadis and Charis Roussos and Federica Finetti and Martina Monti and Lucia Morbidelli and Andreas Papapetropoulos",
year = "2010",
month = "11",
day = "1",
doi = "10.1016/j.vph.2010.08.004",
language = "English (US)",
volume = "53",
pages = "215--222",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "5-6",

}

TY - JOUR

T1 - PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis

AU - Koika, Vasiliki

AU - Zhou, Zongmin

AU - Vasileiadis, Ioannis

AU - Roussos, Charis

AU - Finetti, Federica

AU - Monti, Martina

AU - Morbidelli, Lucia

AU - Papapetropoulos, Andreas

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Vascular endothelial growth factor (VEGF) stimulates nitric oxide (NO) production, which mediates many of its angiogenic actions. However, the angiogenic pathways that operate downstream of NO following VEGF treatment are not well characterized. Herein, we used DT-2 and DT-3, two highly selective cGMP-dependent protein kinase I peptide inhibitors to determine the contribution of PKG-I in VEGF-stimulated angiogenesis. Incubation of chicken chorioallantoic membranes (CAM) with PKG-I peptide inhibitors decreased vascular length in a dose-dependent manner, with DT-3 being more effective than DT-2. Moreover, inhibition of PKG-I with DT-3 abolished the angiogenic response elicited by VEGF in the rabbit eye cornea. PKG-I inhibition also blocked VEGF-stimulated vascular leakage. In vitro, treatment of cells with VEGF stimulated phosphorylation of the PKG substrate VASP through VEGFR2 activation; the VEGF-stimulated VASP phosphorylation was reduced by DT-2. Pre-treatment of cells with DT-2 or DT-3 inhibited VEGF-stimulated mitogen-activated protein kinase cascades (ERK1/2 and p38), growth, migration and sprouting of endothelial cells. The above observations taken together identify PKG-I as a downstream effector of VEGFR2 in EC and provide a rational basis for the use of PKG-I inhibitors in disease states characterized by excessive neovascularization.

AB - Vascular endothelial growth factor (VEGF) stimulates nitric oxide (NO) production, which mediates many of its angiogenic actions. However, the angiogenic pathways that operate downstream of NO following VEGF treatment are not well characterized. Herein, we used DT-2 and DT-3, two highly selective cGMP-dependent protein kinase I peptide inhibitors to determine the contribution of PKG-I in VEGF-stimulated angiogenesis. Incubation of chicken chorioallantoic membranes (CAM) with PKG-I peptide inhibitors decreased vascular length in a dose-dependent manner, with DT-3 being more effective than DT-2. Moreover, inhibition of PKG-I with DT-3 abolished the angiogenic response elicited by VEGF in the rabbit eye cornea. PKG-I inhibition also blocked VEGF-stimulated vascular leakage. In vitro, treatment of cells with VEGF stimulated phosphorylation of the PKG substrate VASP through VEGFR2 activation; the VEGF-stimulated VASP phosphorylation was reduced by DT-2. Pre-treatment of cells with DT-2 or DT-3 inhibited VEGF-stimulated mitogen-activated protein kinase cascades (ERK1/2 and p38), growth, migration and sprouting of endothelial cells. The above observations taken together identify PKG-I as a downstream effector of VEGFR2 in EC and provide a rational basis for the use of PKG-I inhibitors in disease states characterized by excessive neovascularization.

KW - Angiogenesis

KW - CGMP

KW - PKG

KW - Vascular endothelium

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=78449231585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449231585&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2010.08.004

DO - 10.1016/j.vph.2010.08.004

M3 - Article

C2 - 20813203

AN - SCOPUS:78449231585

VL - 53

SP - 215

EP - 222

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 5-6

ER -